Platinum Compounds
From Glioblastoma Treatments
Property | Information |
---|---|
Drug Name | Platinum Compounds (Cisplatin) |
FDA Approval | Yes |
Used for | Glioblastoma |
Clinical Trial Phase | Various, including Phase II |
Clinical Trial Explanation | Not specified |
Common Side Effects | Nephrotoxicity, ototoxicity, and neurotoxicity |
OS without | Not specified |
OS with | Not specified |
PFS without | Not specified |
PFS with | Not specified |
Usefulness Rating | 3 |
Usefulness Explanation | Not specified |
Toxicity Level | Not specified |
Toxicity Explanation | Not specified |
Notes: Combining Temodar with cisplatin has shown improved PFS-6 in recurrent tumors. A protocol combining Temodar, cisplatin, and etoposide reported median survival of 25 months.
From Ben Williams Book: Not specified
Loading comments...